Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIUM: Prasugrel Monotherapy Following Primary PCI for STEMI
NCT05709626Phase 4Recruiting
- Sponsor
- Kindai University
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Kindai University. Primary endpoint: Major adverse cardiovascular events at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
prasugrel
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05709626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709626.